RESUMO
Discrete papular lichen myxedematosus (DPLM), asubset of localized lichen myxedematosus, is a rarecutaneous mucinosis of unknown etiology. We reporta case of a 57-year-old woman with palmoplantarpsoriasis who developed DPLM 8 weeks after addingustekinumab to a long-term course of methotrexate.The patient had previously failed 2 prior tumor necrosisfactor (TNF) inhibitors, adalimumab and etanercept.This case demonstrates an association between TNFinhibitor and ustekinumab use in a psoriasis patientand localized lichen myxedematosus for the secondtime in the literature. The presented case is of interestbecause of the rare diagnosis of DPLM, especially inassociation with the start of the anti-IL 12/23 agentustekinumab. The appearance of DPLM in this settingsuggests a possible etiology for the disease.
Assuntos
Fármacos Dermatológicos/uso terapêutico , Dermatoses Faciais/diagnóstico , Psoríase/tratamento farmacológico , Escleromixedema/diagnóstico , Ustekinumab/uso terapêutico , Dermatoses Faciais/patologia , Dermatoses Faciais/cirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Escleromixedema/patologia , Escleromixedema/cirurgiaRESUMO
IMPORTANCE: UV phototherapy remains a useful and frequently employed treatment for chronic plaque psoriasis. In those patients with plaque body surface area less than 10%, targeted treatment is the safest and most effective modality. OBJECTIVE: We aimed to evaluate the efficacy of the Levia® localized NB-UVB phototherapy machine in the treatment of patients with symmetrical psoriatic lesions. DESIGN: We performed a prospective, double-blinded, sham-treatment controlled study of this device beginning March 2012 through April 2014. SETTING: a comprehensive dermatology clinic in the northeastern United States. PARTICIPANTS: 21 subjects with chronic plaque psoriasis. INTERVENTIONS: Each patient had one lesion randomized to receive the Levia treatment and one lesion (the control) treated with visible light. Treatment was administered three times a week for twelve weeks. Target lesion score (TLS), a rating of 0-4 each of erythema, scaling, and thickness, was measured biweekly by a blinded assessor, and visual analogue scale of pruritus was recorded by subjects. MAIN OUTCOMES AND MEASURES: The primary outcome, formulated prior to study initiation, was the percentage of lesions achieving clear or almost clear TLS after 12 weeks of treatment. Secondary endpoints included changes in target lesion pruritus VAS, percentage improvement in TLS, and the percentage of subjects achieving 50% improvement in TLS (TLS-50). RESULTS: The primary endpoint, TLS of three or less, was not achieved (P=0.118), but the secondary endpoints of percentage improvement in TLS (P=0.043) and TLS-50 (P=0.0195) were significantly superior in treated compared to sham-treated lesions. Percentage improvement in pruritus VAS was not significant (P=0.0565). CONCLUSIONS AND RELEVANCE: This device was found to be efficacious, though not necessarily to the point of clearance, in the treatment of psoriasis over a 12-week period. TRIAL REGISTRATION: www.clinicaltrials.gov, identifier: NCT02107482, http://clinicaltrials.gov/show/NCT02107482
Assuntos
Psoríase/radioterapia , Terapia Ultravioleta , Adulto , Método Duplo-Cego , Feminino , Humanos , Masculino , Estudos Prospectivos , Psoríase/patologia , Índice de Gravidade de Doença , Resultado do Tratamento , Escala Visual AnalógicaRESUMO
Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13, was used to successfully induce remission of chronic, disseminated eczema herpeticum in a six-year-old girl who has DOCK8-deficiency hyper-IgE syndrome. The patient was started on 200 mg of dupilumab administered once every four weeks. The patient had achieved complete resolution of all active herpetic lesions by the time her third dose was due. During the course of three months, she had not developed any new lesions, and significant improvement of the patient's skin, scalp, hair restoration, and nails was appreciated.
RESUMO
Atopic dermatitis (AD) is a chronic immune-mediated disease characterized by intense pruritis, causing inflammation, itching, and redness of the skin. Dupilumab is a human monoclonal antibody that has been approved for the treatment of atopic dermatitis. It has also been linked with various adverse effects, most of them confined to the injection site. Café-au-lait-macules are benign pigmented lesions of the skin, usually seen in people with genetic disorders. We present a case of café-au-lait macules as an adverse effect of dupilumab therapy in a patient with atopic dermatitis. The patient in this case had been receiving dupilumab therapy for atopic dermatitis. The eczematous lesions had seen improvement; however, the patient presented with CALMs on follow-up, which seem to be linked with dupilumab therapy.